Organovo Holdings Stock (NASDAQ:ONVO), Trade Ideas

Organovo Holdings

Organovo Holdings Inc is a biotechnology company, which designs and creates functional and three-dimensional human tissues for medical research and therapeutic applications. It also develops and commercializes a platform technology for the generation of three-dimensional human tissues that can be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. The company collaborates with pharmaceutical and academic partners to develop human biological disease models in three dimensions. Organovo's key instrument platform is the NovoGen Bioprinter. The firm's 3-D bioprinting technologies create tissues using living cells and biocompatible hydrogels.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

ADIL

AEYE

Alterity Therapeutics Limited - American Depositary Shares

ATHE

BHVN

BTCY

CENX

CMAX

Envoy Medical, Inc. - Class A Common Stock

COCH

DXYZ

EGIO

EXTR

HUBC

IMCC

INFA

KAVL

KUKE

LGVN

LOCL

MNDR

MRNS

NMRA

Nuveen California Dividend Advantage Municipal Fund 2

NXPL

ONVO

PROK

PSNY

QTTB

RARE

RENT

SNGX

SNPO

SPCB

SPWR

SRFM

SWVL

TCON

VERU

VIAO

WIRE

Shares of  Ultragenyx Pharmaceutical Inc.  (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic disorder causing developmental disabilities and nerve-related symptoms.

Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday&#39;s Mid-Day Session

Genetic,Research,And,Biotech,Science,Concept.,Human,Biology,And,Pharmaceutical

Organovo released the complete details of its 16-week, randomized, placebo-controlled, multi-center Phase 2 study of the non-steroidal, non-bile acid FXR agonist FXR314 for the treatment of metabolic function-associated steatohepatitis (MASH). 

Why Organovo Stock Is Up Today

Earnings

Eurozone

Commodities

Global

PXMD

U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 300 points on Monday.

The Dow traded up 0.89% to 38,321.05 while the NASDAQ rose 0.70% to 16,288.03. The S&amp;P 500 also rose, gaining, 0.80% to 5,164.30.

Dow Jumps Over 300 Points; Goldman Sachs Posts Upbeat Earnings

Organovo Holdings Inc

<h3>Gainers</h3>
<ul>
<li>Dynatronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYNT#NASDAQ">DYNT</a>) stock rose 84.9% to $0.69 during Tuesday's pre-market session. The company's market cap stands at $3.3 million. </li>
<li>BioRestorative Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRTX#NASDAQ">BRTX</a>) shares rose 23.48% to $1.63. The market value of their outstanding shares is at $11.0 million. </li>
<li>Akanda (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKAN#NASDAQ">AKAN</a>) shares increased by 23.0% to $0.14. The company's market cap stands at $1.6 million. </li>
<li>Cullinan Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGEM#NASDAQ">CGEM</a>) shares moved upwards by 20.89% to $20.01. The company's market cap stands at $861.6 million. </li>
<li>Intra-Cellular Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) stock moved upwards by 18.85% to $76.97. The market value of their outstanding shares is at $7.4 billion. </li>
<li>Alzamend Neuro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALZN#NASDAQ">ALZN</a>) shares moved upwards by 15.07% to $0.85. The market value of their outstanding shares is at $5.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Inovio Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) shares fell 24.3% to $8.32 during Tuesday's pre-market session. The company's market cap stands at $194.4 million. </li>
<li>Calidi Biotherapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CLDI#AMEX">CLDI</a>) stock decreased by 22.5% to $0.47. The market value of their outstanding shares is at $16.5 million. </li>
<li>Dermata Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRMA#NASDAQ">DRMA</a>) stock decreased by 20.06% to $0.24. The market value of their outstanding shares is at $1.5 million. </li>
<li>Addex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADXN#NASDAQ">ADXN</a>) shares declined by 12.69% to $21.61. The company's market cap stands at $22.8 million. </li>
<li>Poseida Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTX#NASDAQ">PSTX</a>) shares fell 12.66% to $2.12. The market value of their outstanding shares is at $204.7 million. </li>
<li>Organovo Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONVO#NASDAQ">ONVO</a>) shares decreased by 10.38% to $1.21. The company's market cap stands at $12.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADXN

AKAN

ALZN

BRTX

CGEM

CLDI

DRMA

DYNT

ITCI

PSTX

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rare#NASDAQ">RARE</a>) fell sharply during Monday&rsquo;s session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic disorder causing developmental disabilities and nerve-related symptoms.
Ultragenyx Pharmaceutical shares dipped 9.4% to $42.46 on Monday.
Here are some other stocks moving in today&#39;s mid-day session.
<h3>Gainers</h3>
<ul>
<li>Soligenix, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sngx#NASDAQ">SNGX</a>) shares surged 71.5% to $0.6679 after the company announced that it was granted orphan drug designation to the active ingredient in MarVax for the prevention and post-exposure prophylaxis against MARV infection by the FDA.</li>
<li>Longeveron Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lgvn#NASDAQ">LGVN</a>) surged 54% to $2.6350 following insider buys from multiple company executives.</li>
<li>SuperCom Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/spcb#NASDAQ">SPCB</a>) shares gained 39.4% to $0.3849 after jumping around 18% on Friday.</li>
<li>Piedmont Lithium Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pll#NYSE">PLL</a>) shares gained 32.1% to $16.75 following a 5% decline on Friday.</li>
<li>Snap One Holdings Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/snpo#NASDAQ">SNPO</a>) surged 31.6% to $10.71 after the company announced that it will be acquired by Resideo Technologies.</li>
<li>Organovo Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/onvo#NASDAQ">ONVO</a>) shares surged 30.9% to $1.32 after the company announced Phase 2 results for FXR314. Study results demonstrated statistically significant reduction in liver fat content from baseline in patients receiving FXR314 compared to placebo.</li>
<li>Kuke Music Holding Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kuke#NASDAQ">KUKE</a>) jumped 27% to $2.7650.</li>
<li>HUB Cyber Security Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hubc#NASDAQ">HUBC</a>) gained 24% to $1.61 after gaining over 11% on Friday.</li>
<li>Edgio, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/egio#NASDAQ">EGIO</a>) gained 24% to $22.18.</li>
<li>Kaival Brands Innovations Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kavl#NASDAQ">KAVL</a>) surged 23.6% to $3.30.</li>
<li>Envoy Medical, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/coch#NASDAQ">COCH</a>) gained 22.6% to $6.19.</li>
<li>Medical Properties Trust, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mpw#NYSE">MPW</a>) rose 19.9% to $4.7850 after the company announced that it sold its majority interest in Utah Hospitals.</li>
<li>CareMax, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cmax#NASDAQ">CMAX</a>) climbed 19.5% to $3.78.</li>
<li>SES AI Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ses#NYSE">SES</a>) surged 18.7% to $1.77.</li>
<li>Mobile-health Network Solutions (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mndr#NASDAQ">MNDR</a>) gained 17.7% to $17.67.</li>
<li>Adial Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adil#NASDAQ">ADIL</a>) rose 16.7% to $2.72.</li>
<li>ProKidney Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/prok#NASDAQ">PROK</a>) gained 16.7% to $2.0426.</li>
<li>Biotricity, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/btcy#NASDAQ">BTCY</a>) rose 16.5% to $1.34.</li>
<li>Yatsen Holding Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ysg#NYSE">YSG</a>) gained 13.3% to $3.41.</li>
<li>Destiny Tech100 Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dxyz#NASDAQ">DXYZ</a>) shares gained 12.8% to $32.71 after dipping 42% on Friday.</li>
<li>Encore Wire Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wire#NASDAQ">WIRE</a>) surged 11.7% to $291.60 after the company entered an agreement to be acquired by Prysmian for $290 per share in cash.</li>
<li>Century Aluminum Company (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cenx#NASDAQ">CENX</a>) gained 9.5% to $18.05.</li>
<li>Extreme Networks, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/extr#NASDAQ">EXTR</a>) gained 5.7% to $11.31. B. Riley Securities analyst Dave Kang upgraded Extreme Networks from Neutral to Buy and maintained a $14 price target.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Marinus Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrns#NASDAQ">MRNS</a>) shares dipped 77% to $1.6800 after the company provided an update on the Phase 3 RAISE trial and reported preliminary Q1 financial results.</li>
<li>Swvl Holdings Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/swvl#NASDAQ">SWVL</a>) fell 35% to $8.58.</li>
<li>VIA optronics AG (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/viao#NASDAQ">VIAO</a>) dipped 34% to $0.2765.</li>
<li>Veru Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/veru#NASDAQ">VERU</a>) fell 24% to $1.1550. Oppenheimer analyst Leland Gershell reiterated Veru with an Outperform and lowered the price target from $7 to $5.</li>
<li>Rent the Runway, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rent#NASDAQ">RENT</a>) dipped 19.8% to $15.42.</li>
<li>NextPlat Corp (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nxpl#NASDAQ">NXPL</a>) fell 19.8% to $1.50 after jumping 24% on Friday. The company entered into a definitive business combination agreement with its majority-owned subsidiary Progressive Care Inc.</li>
<li>Cyngn Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cyn#NASDAQ">CYN</a>) shares fell 19.1% to $0.1170 after declining around 7% on Friday.</li>
<li>ProMIS Neurosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pmn#NASDAQ">PMN</a>) fell 15.6% to $1.95.</li>
<li>Biohaven Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bhvn#NASDAQ">BHVN</a>) dipped 15.4% to $44.90. Biohaven showcased innovative neuroscience portfolio with 20 presentations at the 2024 AAN Annual Meeting.</li>
<li>Neumora Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nmra#NASDAQ">NMRA</a>) shares declined 15.1% to $11.48 after the FDA placed a clinical hold on the company&#39;s Phase 1 NMRA-266 study.</li>
<li>Alterity Therapeutics Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/athe#NASDAQ">ATHE</a>) dipped 15% to $2.49.</li>
<li>Surf Air Mobility Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/srfm#NASDAQ">SRFM</a>) fell 15% to $0.53.</li>
<li>IM Cannabis Corp (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/imcc#NASDAQ">IMCC</a>) fell 14.2% to $0.5399.</li>
<li>Polestar Automotive Holding Uk Plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/psny#NASDAQ">PSNY</a>) fell 12.7% to $1.2699. On Friday, Cantor Fitzgerald analyst Andres Sheppard reiterated Polestar Automotive with an Overweight and maintained a $5 price target.</li>
<li>Desktop Metal, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dm#NYSE">DM</a>) fell 10.8% to $0.8510.</li>
<li>Local Bounti Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/locl#NYSE">LOCL</a>) declined 10.2% to $2.1550.</li>
<li>Q32 Bio Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/qttb#NASDAQ">QTTB</a>) fell 10% to $26.00.</li>
<li>SunPower Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/spwr#NASDAQ">SPWR</a>) fell 8.3% to $2.2750.</li>
<li>Informatica Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/infa#NASDAQ">INFA</a>) dipped 8.1% to $35.36 amid increased volatility following reports suggesting Salesforce is in talks to buy the company.</li>
<li>TRACON Pharmaceuticals Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tcon#NASDAQ">TCON</a>) declined 8.1% to $2.1699 after falling around 9% on Friday.</li>
<li>NOVONIX Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nvx#NYSE">NVX</a>) declined 7.2% to $2.63.</li>
<li>AudioEye, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aeye#NASDAQ">AEYE</a>) fell 6.6% to $12.86 after declining around 7% on Friday.</li>
<li>OncoCyte Corp (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ocx#NASDAQ">OCX</a>) fell 6.6% to $2.5301. Oncocyte announced a transplant assay partnership agreement with Bio-Rad laboratories.</li>
<li>BlackBerry Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bb#NYSE">BB</a>) fell 6.1% to $2.8650.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/04/38249138/dow-jumps-over-300-points-goldman-sachs-posts-upbeat-earnings"> Dow Jumps Over 300 Points; Goldman Sachs Posts Upbeat Earnings</a>

Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session

<h3>Gainers</h3>
<ul>
<li>Longeveron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGVN#NASDAQ">LGVN</a>) stock moved upwards by 44.4% to $2.44 during Monday's regular session. The market value of their outstanding shares is at $7.7 million. </li>
<li>Mobile-health Network (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDR#NASDAQ">MNDR</a>) shares rose 35.53% to $20.33. The company's market cap stands at $691.2 million. </li>
<li>Jaguar Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) shares moved upwards by 31.89% to $0.12. The company's market cap stands at $32.8 million. </li>
<li>Soligenix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNGX#NASDAQ">SNGX</a>) stock increased by 30.35% to $0.5. The market value of their outstanding shares is at $5.2 million. </li>
<li>ProKidney (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PROK#NASDAQ">PROK</a>) stock increased by 26.33% to $2.21. The company's market cap stands at $136.2 million. </li>
<li>Organovo Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONVO#NASDAQ">ONVO</a>) shares moved upwards by 24.58% to $1.26. The market value of their outstanding shares is at $12.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Marinus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNS#NASDAQ">MRNS</a>) shares fell 79.8% to $1.52 during Monday's regular session. The market value of their outstanding shares is at $83.4 million. </li>
<li>Alterity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHE#NASDAQ">ATHE</a>) stock decreased by 20.07% to $2.35. The company's market cap stands at $20.5 million. </li>
<li>BioSig Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSGM#NASDAQ">BSGM</a>) stock decreased by 18.76% to $1.1. The market value of their outstanding shares is at $10.3 million. </li>
<li>Rallybio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLYB#NASDAQ">RLYB</a>) shares fell 18.16% to $1.8. The market value of their outstanding shares is at $74.6 million. </li>
<li>MSP Recovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIFW#NASDAQ">LIFW</a>) stock fell 17.42% to $0.94. The market value of their outstanding shares is at $13.9 million. As per the news, the Q4 earnings report came out today. </li>
<li>China SXT Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTC#NASDAQ">SXTC</a>) stock declined by 17.15% to $1.16. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BSGM

JAGX

LIFW

RLYB

SXTC

12 Health Care Stocks Moving In Monday's Intraday Session

Organovo Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONVO#NASDAQ">ONVO</a>) shares are trading higher Monday after the company announced <a href="https://www.benzinga.com/news/earnings/24/04/38249138/dow-jumps-over-300-points-goldman-sachs-posts-upbeat-earnings">Phase 2 results for FXR314.&nbsp;</a>
The Details:
Organovo<a href="https://www.benzinga.com/pressreleases/24/04/g38246154/organovo-announces-positive-phase-2-results-for-fxr314-in-metabolic-dysfunction-associated-steatoh"> released </a>the complete details of its 16-week, randomized, placebo-controlled, multi-center Phase 2 study of the non-steroidal, non-bile acid FXR agonist FXR314 for the treatment of metabolic function-associated steatohepatitis (MASH).&nbsp;
Study results demonstrated statistically significant reduction in liver fat content from baseline in patients receiving FXR314 compared to placebo, and FXR314 was also found to be safe and well tolerated.
&#8220;The key findings of this study are that once daily oral FXR314 demonstrated statistically significant liver fat reduction and excellent tolerability. Whereas other FXR agonists have had challenges in providing clear benefit without significant pruritus or other adverse events, or have had lack of efficacy potentially related to lack of sustained exposure, we are pleased to note FXR314&#8217;s data demonstrate it clearly rises above previous problems seen with the class,&#8221; stated Keith Murphy, Organovo&#8217;s Executive Chairman. 
Organovo shares are moving on heavy trading volume following the release of Phase 2 results Monday. According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, more than 45 million shares have already been traded in the session, compared to the stock&#8217;s 100-day average of less than 102,000 shares.
Related News: <a href="https://www.benzinga.com/news/24/04/38227765/whats-going-on-with-palantir-stock">What&#8217;s Going On With Palantir Stock?</a>
Is ONVO A Good Stock To Buy?
An investor can make a few decisions when deciding whether a stock is a good buy. In addition to valuation metrics and price action which you can find on Benzinga's quote pages &#8211; like <a href="https://www.benzinga.com/quote/ONVO">Organovo Holdings</a>&#8216;s page for example &#8211; there are factors like whether or not a company pays a dividend or buys a large portion of its stock each quarter.
These are known as capital allocation programs. Organovo Holdings does not pay a dividend, but obviously has a few ways it can return value to shareholders. Feel free to search Benzinga's <a href="https://www.benzinga.com/calendars/dividends">dividend calendar</a> for the next company that is due to pay a dividend and determine what kind of yield you can earn for holding a share of the company.
For example, if you're looking to earn an annualized return of 16.59%, you'll need to buy a share of Orchid Island Cap by the April 29. Once done, you can expect to receive a nominal payout of $0.12 on May. 30.
Buyback programs are obviously different and highly variable. A company can approve a buyback program and purchase shares as it sees fit over the course of time in which the buyback was authorized. Looking through the latest news on <a href="https://www.benzinga.com/quote/ONVO">Organovo Holdings</a> will often yield whether or not the company has approved a buyback program recently. Buyback programs usually serve as a support for share prices, serving as a backstop for demand.
ONVO Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Organovo Holdings shares are up 29.7% at $1.31 at the time of publication Monday.
Image from Shutterstock

U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 300 points on Monday.
The Dow traded up 0.89% to 38,321.05 while the NASDAQ rose 0.70% to 16,288.03. The S&amp;P 500 also rose, gaining, 0.80% to 5,164.30.
Check This Out: <a href="https://www.benzinga.com/news/24/04/38218786/best-buy-box-and-2-other-stocks-insiders-are-selling"> Best Buy, Box And 2 Other Stocks Insiders Are Selling </a>
&nbsp;
<h3>Leading and Lagging Sectors</h3>
&nbsp;
Financial shares jumped by 1.5% on Friday.
In trading on Friday, real estate shares rose by just 0.3%.
&nbsp;
<h3>Top Headline</h3>
&nbsp;
Goldman Sachs Group Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gs#NYSE">GS</a>) reported better-than-expected first-quarter earnings on Monday.
Goldman Sachs reported revenue of $14.21 billion for the first quarter of 2024, beating the consensus of $12.92 billion. The U.S. financial services giant reported EPS of $11.58, beating the consensus of $8.60.
&nbsp;
<h3>Equities Trading UP</h3>
&nbsp;
Soligenix, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sngx#NASDAQ">SNGX</a>) shares shot up 98% to $0.7699 after the company announced that it was granted orphan drug designation to the active ingredient in MarVax for the prevention and post-exposure prophylaxis against MARV infection by the FDA.
Shares of Longeveron Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lgvn#NASDAQ">LGVN</a>) got a boost, surging 70% to $2.87 following insider buys from multiple company executives.
Organovo Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/onvo#NASDAQ">ONVO</a>) shares were also up, gaining 23% to $1.2613 after the company announced Phase 2 results for FXR314. Study results demonstrated statistically significant reduction in liver fat content from baseline in patients receiving FXR314 compared to placebo.
&nbsp;
<h3>Equities Trading DOWN</h3>
&nbsp;
Marinus Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrns#NASDAQ">MRNS</a>) shares dropped 76% to $1.7680 after the company provided an update on the Phase 3 RAISE trial and reported preliminary Q1 financial results.
Shares of ProMIS Neurosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pmn#NASDAQ">PMN</a>) were down 29% to $1.63.
PaxMedica, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pxmd#NASDAQ">PXMD</a>) was down, falling 23% to $0.6501. PaxMedica, last week, announced the completed execution of three pivotal registration/validation batches of PAX-101.
Also Check This Out:<a href="https://www.benzinga.com/news/24/04/38246593/wall-streets-most-accurate-analysts-views-on-3-tech-stocks-with-over-4-dividend-yields"> Wall Street&#39;s Most Accurate Analysts&#39; Views On 3 Tech Stocks With Over 4% Dividend Yields </a>
&nbsp;
<h3>Commodities</h3>
&nbsp;
In commodity news, oil traded up 0.5% to $85.43 while gold traded down 0.8% at $2,353.50.
Silver traded down 0.6% to $28.075 on Friday, while copper rose 0.1% to $4.2580.
&nbsp;
<h3>Euro zone</h3>
&nbsp;
European shares were higher today. The eurozone&rsquo;s STOXX 600 rose 0.8%, London&rsquo;s FTSE 100 gained 0.1% while Spain&rsquo;s IBEX 35 Index rose 0.6% The German DAX gained 1.4% French CAC 40 climbed 1.3% while Italy&rsquo;s FTSE MIB Index jumped 1.5%.
Industrial production in the eurozone increased by 0.8% month-over-month in February.
&nbsp;
<h3>Asia Pacific Markets</h3>
&nbsp;
Asian markets closed mostly lower on Monday, with Japan&rsquo;s Nikkei 225 falling 0.74%, Hong Kong&rsquo;s Hang Seng Index dropping 0.72%, China&rsquo;s Shanghai Composite gaining 1.26% and India&rsquo;s S&amp;P BSE Sensex dipping 1.14%.
Indian merchandise trade deficit shrank to $15.6 billion in March versus a year-ago gap of $18.1 billion, while wholesale prices rose by 0.53% year-over-year in March versus a 0.20% gain in the prior month.
&nbsp;
<h3>Economics</h3>
&nbsp;
The NY Empire State Manufacturing Index climbed to -14.3 in April versus prior month&rsquo;s reading of -20.9.
Retail sales increased 0.7% month-over-month in March following a revised 0.9% rise in February.
Now Read This: <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38248683/bitcoin-surpasses-66-000-core-emerges-as-top-gainer"> Bitcoin Surpasses $66,000; Core Emerges As Top Gainer </a>

WIIM

Organovo shares are trading higher after the company announced Phase 2 results for FXR314. Study results demonstrated statistically significant reduction in liver fat content from baseline in patients receiving FXR314 compared to placebo.

GS: 4.5% &#x7C;&nbsp;<a href="https://www.benzinga.com//node/38245445">Goldman Sachs shares are trading higher after the company reported better-than-expected Q1 EPS and revenues.</a>
LGVN: 82% &#x7C;&nbsp;<a href="https://www.benzinga.com//node/38246876">Longeveron&#39;s CLEAR MIND Randomized Phase 2a Clinical Trial Evaluating Lomecel-B In Mild Alzheimer&#39;s Disease Accepted For Featured Research Session Oral Presentation At 2024 AAIC</a>
ONVO: 65% &#x7C;&nbsp;<a href="https://www.benzinga.com//node/38246185">Organovo Announces Phase 2 Results For FXR314; Says &#39;Study subjects receiving FXR314 achieved statistically significant reduction in liver fat content from baseline&#39;</a>

Market-Moving News for April 15th

Biotech

General

Organovo Announces Phase 2 Results For FXR314; Says 'Study subjects receiving FXR314 achieved statistically significant reduction in liver fat content from baseline'

Shares of Medical Properties Trust, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mpw#NYSE">MPW</a>) rose sharply in today&rsquo;s pre-market trading after the company announced that it sold its majority <a href="https://www.benzinga.com/quote/MPW/news">interest in Utah Hospitals</a>.
Medical Properties Trust shares jumped 13.1% to $4.51 in pre-market trading.
Here are some other stocks moving in pre-market trading.
<h3>Gainers</h3>
<ul>
<li>Allarity Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/allr#NASDAQ">ALLR</a>) shares rose 51% to $3.17 in pre-market trading after dipping 9% on Friday. Allarity Therapeutics filed prospectus supplement to increase offering price of common stock that may be offered from $2.35 million to $3.2 million.</li>
<li>Longeveron Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lgvn#NASDAQ">LGVN</a>) gained 38.4% to $2.34 in pre-market trading after falling 16% on Friday. Longeveron, last week, announced closing of $5.2 million public offering.</li>
<li>SuperCom Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/spcb#NASDAQ">SPCB</a>) shares gained 34.8% to $0.3722 in pre-market trading after jumping around 18% on Friday.</li>
<li>HUB Cyber Security Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hubc#NASDAQ">HUBC</a>) climbed 29.2% to $1.68 in pre-market trading after gaining over 11% on Friday.</li>
<li>Piedmont Lithium Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pll#NYSE">PLL</a>) shares gained 22.2% to $15.49 in pre-market trading following a 5% decline on Friday.</li>
<li>Marine Petroleum Trust (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/marps#NASDAQ">MARPS</a>) gained 12.3% to $6.04 in pre-market trading after jumping 18% on Friday.</li>
<li>Destiny Tech100 Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dxyz#NASDAQ">DXYZ</a>) shares gained 11.4% to $32.31 in pre-market trading after dipping 42% on Friday.</li>
<li>Kineta, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ka#NASDAQ">KA</a>) shares rose 8.7% to $0.3989 in pre-market trading after falling 17% on Friday.</li>
<li>LendingClub Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/lc#NYSE">LC</a>) shares gained 8.7% to $8.79 in pre-market trading. LendingClub is expected to report earnings for the first quarter 2024 after the closing bell on Tuesday, April 30, 2024.</li>
</ul>
<h3>
Losers</h3>
<ul>
<li>AudioEye, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aeye#NASDAQ">AEYE</a>) fell 24.1% to $10.45 in pre-market trading after declining around 7% on Friday.</li>
<li>NextPlat Corp (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nxpl#NASDAQ">NXPL</a>) fell 19.8% to $1.50 in pre-market trading after jumping 24% on Friday. The company entered into a definitive business combination agreement with its majority-owned subsidiary Progressive Care Inc.</li>
<li>Organovo Holdings Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/onvo#NASDAQ">ONVO</a>) shares declined 15.8% to $0.85 in pre-market trading.</li>
<li>TRACON Pharmaceuticals Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tcon#NASDAQ">TCON</a>) declined 15.3% to $2.00 in pre-market trading after falling around 9% on Friday.</li>
<li>IM Cannabis Corp (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/imcc#NASDAQ">IMCC</a>) fell 14.2% to $0.54 in pre-market trading.</li>
<li>OncoCyte Corp (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ocx#NASDAQ">OCX</a>) fell 14.1% to $2.33 pre-market trading. Oncocyte announced a transplant assay partnership agreement with Bio-Rad laboratories</li>
<li>&nbsp;</li>
<li>Cyngn Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cyn#NASDAQ">CYN</a>) shares fell 13.6% to $0.12 in pre-market trading after declining around 7% on Friday.</li>
<li>SINTX Technologies Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sint#NASDAQ">SINT</a>) fell 12.6% to $0.021 in pre-market trading after declining around 4% on Friday.</li>
<li>&nbsp;</li>
<li>Biophytis SA (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bpts#NASDAQ">BPTS</a>) shares fell 7.4% to $0.31 in pre-market trading.</li>
<li>Polestar Automotive Holding Uk Plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/psny#NASDAQ">PSNY</a>) fell 7.2% to $1.35 pre-market trading. On Friday, Cantor Fitzgerald analyst Andres Sheppard reiterated Polestar Automotive with an Overweight and maintained a $5 price target.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/04/38242305/goldman-sachs-likely-to-report-lower-q1-earnings-here-are-the-recent-forecast-changes-from-wall-str"> Goldman Sachs Likely To Report Lower Q1 Earnings; Here Are The Recent Forecast Changes From Wall Street&#39;s Most Accurate Analysts</a>

Pre-Market Outlook

ALLR

BPTS

MARPS

SINT

Why Medical Properties Trust Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket

<h3>Gainers</h3>
<ul>
<li>Renalytix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNLX#NASDAQ">RNLX</a>) stock rose 490.4% to $2.25 during Monday's regular session. The market value of their outstanding shares is at $112.4 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) stock rose 39.91% to $10.39. The market value of their outstanding shares is at $135.2 million. </li>
<li>Genenta Science (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNTA#NASDAQ">GNTA</a>) shares increased by 31.84% to $4.14. The market value of their outstanding shares is at $75.4 million. </li>
<li>T2 Biosystems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTOO#NASDAQ">TTOO</a>) stock rose 29.94% to $6.35. The company's market cap stands at $25.7 million. </li>
<li>Sangamo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) stock moved upwards by 26.04% to $0.72. The company's market cap stands at $128.3 million. </li>
<li>Organovo Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONVO#NASDAQ">ONVO</a>) shares moved upwards by 25.55% to $1.13. The market value of their outstanding shares is at $11.3 million. As per the press release, Q3 earnings came out 2 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>AN2 Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANTX#NASDAQ">ANTX</a>) stock decreased by 75.0% to $5.01 during Monday's regular session. The company's market cap stands at $149.0 million. </li>
<li>InVivo Therapeutics Hldg (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVIV#NASDAQ">NVIV</a>) shares declined by 33.39% to $0.33. The company's market cap stands at $1.0 million. </li>
<li>TC BioPharm (Holdings) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBP#NASDAQ">TCBP</a>) shares fell 28.95% to $1.08. </li>
<li>NanoString Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSTG#NASDAQ">NSTG</a>) shares declined by 22.18% to $0.18. The market value of their outstanding shares is at $8.6 million. </li>
<li>Intelligent Bio Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INBS#NASDAQ">INBS</a>) stock decreased by 18.58% to $5.51. The company's market cap stands at $4.0 million. The company's, Q2 earnings came out yesterday. </li>
<li>OneMedNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) shares decreased by 18.18% to $0.9. The market value of their outstanding shares is at $29.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ANTX

GNTA

Intelligent Bio Solutions Inc. - Common Stock

INBS

NSTG

NVIV

ONMD

RNLX

SGMO

TCBP

TTOO

The presentation highlights preclinical data characterizing the activity of FXR314 in 3D models of human Crohn's disease and ulcerative colitis. FXR314 broadly improved measures of epithelial barrier function in a subset of donors, and fibrotic markers in all Crohn's disease donors. In ulcerative colitis, FXR314 improved epithelial barrier function and fibrotic activity in all donors.

Organovo Presents FXR314 3D Human Tissue Model Findings

Organovo To Release Final And Complete Data From Phase 2a Trial Of FXR314 In Apr. 2024

Organovo Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONVO#NASDAQ">ONVO</a>), a clinical stage biotechnology company that is focused on developing FXR314 in ulcerative colitis and inflammatory bowel disease (IBD), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as strong preclinical data, today announced its intention to study combination therapy in inflammatory bowel disease and release data in calendar Q3 2024. The Company believes that the data it can generate can be powerful in establishing a strong use case for FXR314 in patients, and provide support for collaborations with major pharmaceutical companies currently offering IBD treatments. &nbsp;
The differentiated mechanism of action of FXR314, as highlighted in Organovo's recently provided mechanism of action video at <a href="https://www.globenewswire.com/Tracker?data=fL7zfR21LFUM30Ohfb2VlYPbVRcrcix5fm0qZzEBmGD_0Vvo3PBism1wwSd1d3loih9h9FdK0-cdW5iz1AjzDg==">http://organovo.com</a>, provides substantial promise that the drug's impact will strongly complement the biology of other successful drugs in the space, e.g. TNF-alpha inhibitors (such as Humira), IL-12/23 inhibitors (such as Stelara), and JAK inhibitors (such as Xeljanz). The promise of combination therapy in this space is great, as all of these therapies have impactful safety signals. The ability to enable dosing half or less of the typical dose of these drugs, enabled by a combination with FXR314, could substantially reduce the safety impact and better serve patients. Further, FXR314 combination therapy could enable the successful achievement of clinical remission in a greater percentage of patients.
In both Organovo's proprietary 3D human models and in preclinical animal models of disease, FXR314 treatment demonstrates a reduction in the disruption of the intestinal lining, which protects against bacteria penetrating into the intestinal wall. Further, our models and published literature1 indicate a role of FXR314 in modulating responses in innate lymphoid cells (ILCs) in the intestine, preventing the cytokine release that triggers a systemic immune-inflammatory response. In so doing, FXR314 can complement the typical drug therapies used in IBD, which themselves inhibit the activity of the cytokines driving the systemic response. Since FXR314 has a target that is upstream of most currently prescribed drugs, it can potentially strongly complement the use of these drugs when used in combination.
Organovo has previously announced plans for a Phase 2a study of FXR314 in ulcerative colitis, with a readout expected in 1H 2025. In addition, the company will now begin preclinical studies with combination therapies using FXR314 and currently approved therapies or equivalent that can benefit from lower dosing. Further, over time the company expects to share data generated in its proprietary 3D human models of inflammatory bowel disease that further demonstrate the potential for combination effects.
"We remain excited about the potential of FXR314 to treat IBD due to its unique mechanism of action, and about our upcoming Phase 2 study to demonstrate its activity in ulcerative colitis," said Keith Murphy, Organovo Executive Chairman. "As we enroll patients and complete the Phase 2, we are eager to explore the drug's potential for combination therapy and share our findings and the opportunities we see to further benefit patients, some of whom don't benefit from existing therapies due to safety limitations or low response rates. There remains great unmet need in inflammatory bowel disease, and we look forward to defining multiple roles FXR314 can play in providing treatment solutions."

Organovo Highlights FXR314 Combination Therapy Potential And Plan

<h3>Gainers</h3>
<ul>
<li>MSP Recovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIFW#NASDAQ">LIFW</a>) shares moved upwards by 481.0% to $15.92 during Monday's regular session. MSP Recovery's stock is trading at a volume of 44.7 million shares as of 12:30 EST. This is 2105.5% of its average full-day volume over the last 100 days. The company's market cap stands at $213.3 million. </li>
<li>Cardio Diagnostics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDIO#NASDAQ">CDIO</a>) shares moved upwards by 64.26% to $0.61. Cardio Diagnostics Hldgs's stock is trading at a volume of 69.7 million shares as of 12:30 EST. This is 1967.8% of its average full-day volume over the last 100 days. The company's market cap stands at $11.5 million. </li>
<li>Aileron Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALRN#NASDAQ">ALRN</a>) stock moved upwards by 26.29% to $1.47. Trading volume for Aileron Therapeutics's stock is 496.4K as of 12:30 EST. This is 1677.1% of its average full-day volume over the last 100 days. The company's market cap stands at $7.1 million. </li>
<li>Candel Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CADL#NASDAQ">CADL</a>) shares rose 25.9% to $0.85. As of 12:30 EST, Candel Therapeutics's stock is trading at a volume of 62.8K, which is 262.1% of its average full-day volume over the last 100 days. The company's market cap stands at $24.5 million. </li>
<li>Synlogic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYBX#NASDAQ">SYBX</a>) shares increased by 25.8% to $2.34. The company's market cap stands at $19.8 million. </li>
<li>PaxMedica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PXMD#NASDAQ">PXMD</a>) shares moved upwards by 23.08% to $3.2. As of 12:30 EST, this security is trading at a volume of 447.0K shares, making up 345.4% of its average full-day volume over the last 100 days. The company's market cap stands at $3.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Novo Integrated Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVOS#NASDAQ">NVOS</a>) shares fell 56.4% to $0.13 during Monday's regular session. As of 12:30 EST, this security is trading at a volume of 59.4 million shares, making up 101.5% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $21.8 million. </li>
<li>Zentalis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZNTL#NASDAQ">ZNTL</a>) stock declined by 24.89% to $13.43. As of 12:30 EST, this security is trading at a volume of 1.5 million shares, making up 226.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $948.2 million. As per the news, the Q3 earnings report came out today. </li>
<li>MoonLake (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLTX#NASDAQ">MLTX</a>) stock declined by 23.36% to $39.3. MoonLake's stock is trading at a volume of 3.5 million shares as of 12:30 EST. This is 685.7% of its average full-day volume over the last 100 days. The company's market cap stands at $2.1 billion. </li>
<li>Evelo Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVLO#NASDAQ">EVLO</a>) stock declined by 19.98% to $0.34. Trading volume for Evelo Biosciences's stock is 1.4 million as of 12:30 EST. This is 391.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $6.4 million. </li>
<li>Oncology Institute (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TOI#NASDAQ">TOI</a>) shares fell 18.29% to $1.65. As of 12:30 EST, Oncology Institute's stock is trading at a volume of 259.5K, which is 129.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $120.4 million. </li>
<li>Organovo Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONVO#NASDAQ">ONVO</a>) shares decreased by 18.24% to $1.39. Trading volume for this security as of 12:30 EST is 174.0K, which is 393.3% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $12.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALRN

CADL

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

EVLO

MLTX

NVOS

SYBX

ZNTL

<h3>Gainers</h3>
<ul>
<li>Sensei Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNSE#NASDAQ">SNSE</a>) shares moved upwards by 13.0% to $0.78 during Friday's after-market session. The market value of their outstanding shares is at $20.7 million. </li>
<li>Qilian Intl Hldg Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QLI#NASDAQ">QLI</a>) stock rose 10.69% to $0.62. At the close, Qilian Intl Hldg Gr's trading volume reached 108.4K shares. This is 2982.1% of its average volume over the last 100 days. The company's market cap stands at $22.1 million. </li>
<li>Passage Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PASG#NASDAQ">PASG</a>) stock moved upwards by 9.74% to $0.72. The company's market cap stands at $39.4 million. </li>
<li>MiNK Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INKT#NASDAQ">INKT</a>) stock increased by 9.4% to $1.28. The company's market cap stands at $44.1 million. </li>
<li>Inovio Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) shares increased by 6.32% to $0.42. Trading volume for this security closed at 148.7K, accounting for 4.3% of its average full-day volume over the last 100 days. The company's market cap stands at $112.5 million. </li>
<li>MultiPlan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPLN#NYSE">MPLN</a>) stock increased by 6.06% to $1.75. The market value of their outstanding shares is at $1.1 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Acurx Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACXP#NASDAQ">ACXP</a>) shares decreased by 14.6% to $2.8 during Friday's after-market session. At the close, Acurx Pharmaceuticals's trading volume reached 71.1K shares. This is 10.4% of its average volume over the last 100 days. The market value of their outstanding shares is at $36.4 million. </li>
<li>NexImmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEXI#NASDAQ">NEXI</a>) stock decreased by 13.66% to $2.53. The market value of their outstanding shares is at $2.6 million. </li>
<li>Sonoma Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNOA#NASDAQ">SNOA</a>) stock fell 8.56% to $0.17. Sonoma Pharmaceuticals's trading volume hit 541.4K shares by close, accounting for 404.4% of its average volume over the last 100 days. The company's market cap stands at $2.3 million. </li>
<li>Organovo Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONVO#NASDAQ">ONVO</a>) shares fell 8.23% to $1.56. The company's market cap stands at $13.6 million. </li>
<li>Aclarion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACON#NASDAQ">ACON</a>) shares declined by 8.22% to $0.3. The company's market cap stands at $2.5 million. </li>
<li>CASI Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CASI#NASDAQ">CASI</a>) stock decreased by 7.37% to $4.4. The company's market cap stands at $58.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACON

ACXP

CASI

INKT

MPLN

NEXI

PASG

SNOA

SNSE

12 Health Care Stocks Moving In Friday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>LianBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIAN#NASDAQ">LIAN</a>) stock increased by 79.8% to $2.5 during Tuesday's pre-market session. The market value of their outstanding shares is at $267.9 million. </li>
<li>TransCode Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) shares increased by 33.85% to $0.41. The company's market cap stands at $4.8 million. </li>
<li>MyMD Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYMD#NASDAQ">MYMD</a>) shares rose 12.56% to $0.43. The company's market cap stands at $19.3 million. </li>
<li>Vivos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VVOS#NASDAQ">VVOS</a>) stock moved upwards by 11.51% to $0.31. The market value of their outstanding shares is at $9.2 million. </li>
<li>Organovo Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONVO#NASDAQ">ONVO</a>) shares moved upwards by 10.89% to $1.31. The market value of their outstanding shares is at $11.4 million. </li>
<li>Revelation Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REVB#NASDAQ">REVB</a>) shares increased by 10.86% to $0.66. The company's market cap stands at $4.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>LumiraDx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMDX#NASDAQ">LMDX</a>) shares decreased by 35.6% to $0.18 during Tuesday's pre-market session. The market value of their outstanding shares is at $56.5 million. </li>
<li>INVO Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INVO#NASDAQ">INVO</a>) shares declined by 21.23% to $1.67. The company's market cap stands at $4.1 million. </li>
<li>Oncology Institute (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TOI#NASDAQ">TOI</a>) shares decreased by 12.5% to $1.33. The market value of their outstanding shares is at $97.0 million. </li>
<li>Citius Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTXR#NASDAQ">CTXR</a>) stock declined by 11.73% to $0.59. The market value of their outstanding shares is at $94.5 million. </li>
<li>SAB Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SABS#NASDAQ">SABS</a>) shares fell 11.35% to $0.86. The market value of their outstanding shares is at $44.9 million. </li>
<li>TC BioPharm (Holdings) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBP#NASDAQ">TCBP</a>) shares decreased by 9.07% to $0.37. The company's market cap stands at $2.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CTXR

INVO

LIAN

LMDX

MyMD Pharmaceuticals, Inc. - Common Stock

MYMD

REVB

RNAZ

SABS

VVOS

Gainers
AERWINS Technologies Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/awin#NASDAQ">AWIN</a>) shares surged 91.2% to $0.2180 in pre-market trading after falling 10% on Monday.
Ascent Solar Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/asti#NASDAQ">ASTI</a>) shares rose 85.2% to $1.82 in pre-market trading after the company said the initial concept paper submitted for DE-FOA-0003057: Bipartisan Infrastructure Law: Silicon Solar Manufacturing, and Dual-use Photovoltaics Incubator has been reviewed and received an &ldquo;Encouraged&rdquo; decision from the Department of Energy.
WiSA Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wisa#NASDAQ">WISA</a>) rose 63.1% to $0.30 in pre-market trading. WiSA Technologies recently announced the pricing of $4.8 million public offering of series B convertible redeemable preferred stock and warrants.
Lytus Technologies Holdings PTV. Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lyt#NASDAQ">LYT</a>) shares gained 19.2% to $0.1930 in pre-market trading.
LM Funding America, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lmfa#NASDAQ">LMFA</a>) shares climbed 17.6% to $0.4847 in pre-market trading after falling 10% on Monday.
Soluna Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/slnh#NASDAQ">SLNH</a>) gained 16.7% to $3.54 in pre-market trading after gaining 13% on Monday.
Organovo Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/onvo#NASDAQ">ONVO</a>) shares rose 12.8% to $1.32 in pre-market trading.
Argo Blockchain plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/arbk#NASDAQ">ARBK</a>) shares jumped 12.8% to $1.23 in pre-market trading after jumping over 12% on Monday.
CleanSpark, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/clsk#NASDAQ">CLSK</a>) rose 13.2% to $4.82 in pre-market trading amid strength in Bitcoin.
Logitech International S.A. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/logi#NASDAQ">LOGI</a>) shares rose 11.1% to $75.90 in pre-market trading as the company posted upbeat second-quarter results and raised its FY24 revenue guidance outlook.
Losers
LumiraDx Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lmdx#NASDAQ">LMDX</a>) dipped 31% to $0.1898 in pre-market trading. LumiraDx shares jumped 216% on Monday after the company announced a strategic collaboration with AstraZeneca and Everton in the Community to set up England&#39;s first community-based heart and lung screening hub.
Markforged Holding Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mkfg#NASDAQ">MKFG</a>) shares fell 18.5% to $0.8799 in pre-market trading. Markforged sees preliminary third-quarter revenue of $20 million and projects 2023 revenue of $90 million to $95 million, which is below the low end of the prior range.
XORTX Therapeutics Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/xrtx#NASDAQ">XRTX</a>) shares fell 16.6% to $0.3510 in pre-market trading after dipping 34% on Monday.
TC Biopharm (Holdings) Plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tcbp#NASDAQ">TCBP</a>) shares fell 16.2% to $0.3410 in pre-market trading after gaining 9% on Monday. TC BioPharm reported the submission of an Investigational New Drug (IND) application to the FDA for the use of TCB-008 in the treatment of relapse/refractory Acute Myeloid Leukemia.
IonQ, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ionq#NASDAQ">IONQ</a>) fell 15.3% to $10.71 in pre-market. IonQ said Dr. Chris Monroe, Chief Science Officer, will leave the company.
The Alkaline Water Company Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wter#NASDAQ">WTER</a>) shares fell 14.1% to $0.1960 in pre-market trading after jumping 14% on Monday.
SeaStar Medical Holding Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/icu#NASDAQ">ICU</a>) shares fell 13.7% to $0.6274 in pre-market trading after declining 29% on Monday.
Alaunos Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tcrt#NASDAQ">TCRT</a>) fell 12.6% to $0.0962 in pre-market trading after climbing around 6% on Monday.
Harpoon Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/harp#NASDAQ">HARP</a>) fell 10.2% to $4.74 in pre-market trading. Harpoon Therapeutics shares fell 23% on Monday after the company announced updated data from a trial evaluating its cancer drug.
INVO Bioscience, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/invo#NASDAQ">INVO</a>) shares fell 9.4% to $1.92 in pre-market trading after jumping over 292% on Monday. The company announced it will acquire NAYA Biosciences in an all-stock transaction.
Now Read This: <a href="https://www.benzinga.com/news/earnings/23/10/35387029/investor-fear-eases-slightly-ahead-of-big-earnings"> Investor Fear Eases Slightly Ahead Of Big Earnings</a>

ARBK

ASTI

AWIN

CLSK

HARP

IONQ

LMFA

LOGI

MKFG

SLNH

TCRT

WISA

WTER

XRTX

Why Logitech International Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving Premarket

<a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11789011">https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11789011</a>
<figure class="image"><img src="https://pbs.twimg.com/media/F8pfGvJa0AAOOCW?format=jpg&amp;name=900x900" alt="Image" /></figure>

Organovo Granted U.S. Patent #11789011 Today For "Engineered Three-Dimensional Breast Tissue Adipose And Tumor Disease Model" Background P1: "Models Disclosed Herein Have Several Advantages Over Current Screening Tools"

Organovo Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/onvo#NASDAQ">ONVO</a>) (Organovo), a clinical stage biotechnology company that is focused on developing novel human therapies with demonstrated function in high fidelity three-dimensional (3D) tissues that recapitulate key aspects of human disease, today announced more details about its clinical program for FXR314, an FXR agonist that has completed initial clinical trials. FXR314 is a drug with safety and tolerability after daily oral dosing in Phase 1 and Phase 2 trials. Further, FXR314 has FDA clinical trial authorization for a Phase 2 trial in ulcerative colitis.
"Phase 1 safety data for FXR314, the data in our 3D human models of ulcerative colitis, and preclinical models all show very positive promise for FXR314 in the treatment of ulcerative colitis," said Keith Murphy, Organovo's Founder and Executive Chairman. "We believe strongly that the fact that FXR314 is showing effects on disease in our 3D human cellular models of ulcerative colitis means that it has a greater likelihood of success in Phase 2 than a typical drug program. We are excited to be charting a path to clinical success in ulcerative colitis, while also seeking to unlock the drug's strong potential in NASH, where it has shown great promise in early clinical trials."
Organovo's FXR program announcement updates its previous guidance on clinical trial starts for the company, with the Company accelerating its timeline to first clinical trials by approximately two years. The Company previously announced in March 2023 that it would give guidance on Phase 2 timelines for FXR314 after an internal determination of the best path forward. The Company continues to expect to file INDs starting in 2025 for fully internally developed molecules and expects to issue additional guidance on pipeline programs in the coming months.
In addition, Organovo is anticipating the release of final Phase 2 data on the performance of FXR314 in NASH. Performance of the drug to date in treatment of NASH has been encouraging. Interim results in Phase 2 showed that FXR314 lowered liver fat content, with mean relative reductions of 26.9±27.8 percent in the 3 mg cohort and 9.3±55.8 percent in the 6 mg cohort, compared with 7.5±21.0 percent in the placebo cohort. Median liver fat reduction was 28.6 percent in the 3 mg cohort, 26.9 percent in the 6 mg cohort compared to 1.5% in the placebo arm. A post-hoc comparative assessment of relative liver fat reduction in the interim cohort found the decrease with the 3 mg dose to be statistically significant compared to placebo (p=0.006). FXR314 achieved greater than 30 percent liver fat reduction in 47 percent of patients (8/17) in the 3 mg cohort and 35 percent (6/17) in the 6 mg cohort, compared with 12 percent (2/17) in the placebo arm. To date, the drug has been generally well-tolerated, with no treatment-related serious adverse events. All treatment-related adverse events have been mild-moderate with no apparent dose relationship. Full Phase 2 data is expected to be released in 1H 2024.

Organovo Advances Clinical Timelines For FXR314 And Provides Updates On NASH Phase 2 Data

Organovo Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONVO#NASDAQ">ONVO</a>), a clinical stage biotechnology company that is focused on developing novel human therapies with demonstrated function in high fidelity three-dimensional (3D) tissues that recapitulate key aspects of human disease, today announced a clinical program for FXR 314, an FXR agonist that has completed initial clinical trials. FXR314 is a drug with safety and tolerability after daily oral dosing in Phase 1 and Phase 2 trials. Further, FXR314 has FDA clinical trial authorization for a Phase 2 trial in ulcerative colitis. 
&nbsp;
&quot;We believe FXR314 to be a best-in-class FXR agonist with high potency and the potential to avoid dose-limiting toxicity issues found in other FXR-directed compounds,&quot; said Keith Murphy, Organovo&#39;s Founder and Executive Chairman. &quot;Our 3D human tissue models will allow us to find the most effective clinical and commercial development strategy for this drug in inflammatory bowel disease patients, and we expect FXRs to have a widening set of therapeutic applications over time.&quot;
Organovo&#39;s FXR program announcement updates its previous&nbsp;guidance&nbsp;that it would first begin Phase 1 trials in 2025. The Company plans to give&nbsp;guidance&nbsp;on Phase 2 timelines after an internal determination of the best path forward. The Company continues to expect to file INDs starting in 2025 from fully internally developed molecules and expects to issue additional&nbsp;guidance&nbsp;on clinical plans in the coming months.

Organovo Announces FXR Program

Organovo Holdings Inc (ONVO) stock is lower by -20.00% over the last 12 months. InvestorsObserver's proprietary ranking system, gives ONVO stock a score of  10 out of a possible 100. That rank is primarily influenced by a long-term technical score of 6. ONVO's rank also includes a short-term technical score of 24.  ONVO ha

Organovo Holdings Inc (ONVO) Stock Rises 5.26% This Week; Should You Buy?

Organovo Holdings Inc (ONVO) is near the bottom in its sector according to InvestorsObserver.ONVO gets an overall rating of 25. That means it scores higher than 25% of stocks.Organovo Holdings Inc gets a 9 rank in the Healthcare sector. Healthcare is number 2 out of 11 sectors. ONVO has an Overall Score of 25. Find out wha

Can Organovo Holdings Inc (ONVO) Stock Rise to the Top of Healthcare Sector Tuesday?

Organovo files for $150M mixed shelf

Organovo Holdings (ONVO) has released an update to notify the public and investors about a regulation fd disclosure. Organovo Holdings, Inc. has sh...

Organovo Holdings Unveils Corporate Presentation Online

The market has been high on Organovo Holdings Inc (ONVO)  stock recently. ONVO gets a Bullish score from InvestorsObserver Stock Sentiment Indicator. Organovo Holdings Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on ONVO!See Full ONVO ReportWhat is Stock Sentiment?S

Should You Buy Organovo Holdings Inc (ONVO) Stock After it Is Higher By 1.94% in a Week?

Organovo Holdings Inc (ONVO) stock is down -48.48% over the last 12 months. InvestorsObserverâ€&#x2122;s proprietary ranking system, gives ONVO stock a score of  6 out of a possible 100. That rank is mainly influenced by a long-term technical score of 7. ONVO's rank also includes a short-term technical score of 10.  ONVO has an Ove

Is Organovo Holdings Inc (ONVO) Stock a Good Value?

Organovo Holdings Inc (ONVO) stock is lower by -52.42% over the last 12 months. InvestorsObserverâ€&#x2122;s proprietary ranking system, gives ONVO stock a score of  3 out of a possible 100. That rank is mainly influenced by a short-term technical score of 2. ONVO's rank also includes a long-term technical score of 8.  ONVO has an

Is Organovo Holdings Inc (ONVO) Stock Worth a Buy Monday?

Organovo files to sell common stock, warrants

Organovo reports positive mid-stage results for FXR314 in metabolic dysfunction-associated steatohepatitis

INDO, ONVO and HUSA among pre-market losers

ATNF

HUSA

INDO

MDJH

PACB

RVYL

SPRC

Press Releases

Organovo Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 Data

Organovo to Participate in the H.C. Wainwright Global Investment Conference

Organovo Highlights FXR314 Combination Therapy Potential and Plan

Health Care

Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results

-

-

-

-

-

-

-

25% Off Benzinga's Most Powerful Trading Tools

-

-

-

-

-

-

-

Organovo Holdings Stock (NASDAQ:ONVO), Trade Ideas